Business
INTIVA BioPharma Inc. Announces Name Change to Nexien BioPharma Inc.
INTIVA BioPharma Inc. Announces Name Change to Nexien BioPharma Inc..
About this update from Nexien Biopharma, Inc.
[{"type":"text","content":"DENVER, CO / ACCESSWIRE / October 1, 2018 / Intiva BioPharma Inc. (OTCQB: NTVA) (the \"Company\") announces that the Company has changed its corporate name to Nexien BioPharma Inc. (\"Nexien\"). The new corporate name, Nexien BioPharma, was inspired by the Company's mission of becoming a global leader in the further evolution of cannabinoid science and the development of Food and Drug Administration (\"FDA\") compliant pharmaceuticals based on specific cannabinoid molecules. \"Cannabinoid science and the development of cannabinoid-based pharmaceuticals is the core of Nexien's business. The decision to change our Company's name was made based on the desire to have a name that better reflects the Company's intent to become a leading cannabinoid-science and pharmaceutical development company, one that is focused on the exciting development of the next generation of cannabinoid-based pharmaceuticals,\" stated Alain Bankier, Nexien's Interim CEO.Rob Goldfarb Nexien’s COO, also stated, \"Key to the decision to change the Company's name was the fact that the name Intiva Biopharma was often associated with the cannabis plant as opposed to the Company's business of cannabinoid science and the development of cannabinoid-based pharmaceuticals.\"In a seamless transition for shareholders, the Company will continue to trade on the OTC Markets QB under the stock symbol NTVA, although it is anticipated that the stock symbol will be changed in the near future. Securities held in brokerage accounts or \"electronically\" at the transfer agent will automatically be changed to securities of Nexien BioPharma Inc. with the new CUSIP number. About Nexien BioPharmaNexien BioPharma is a US-based pharmaceutical development company engaged in the formulation, development, and commercialization of cannabinoid-based pharmaceuticals in accordance with U.S. Food and Drug Administration (\"FDA\") pre-clinical and clinical pathways, to address a broad range of medical conditions and disorders.Nexien BioPharma's drug development strategy consists of: The determination of medical conditions and disorders that could potentially benefit from cannabinoid-based formulations; Conducting \"freedom to operate\" investigations on these conditions; The preparation of patent applications and the prosecution of such application and/or the licensing of existing patents;...